# An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Source: https://onco.cc/trials/nct03844048/  
OnCo record `nct03844048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Venetoclax in multiple myeloma and non-hodgkin lymphoma, run by AbbVie, active and no longer recruiting.

## Summary

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is a phase 3 interventional study registered as NCT03844048 by AbbVie, with 165 participants enrolled, started 2019-09-06 and due to reach its primary completion in 2027-08. Interventions recorded: Venetoclax. Conditions listed: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03844048
- Phase: 3
- Setting: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
- Sponsor: AbbVie
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT03844048: https://clinicaltrials.gov/study/NCT03844048

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03844048.json